MedVellum
MedVellum
Back to Library
Paediatrics
Infectious Diseases
Obstetrics
Public Health

Rubella (German Measles)

High EvidenceUpdated: 2025-12-25

On This Page

Red Flags

  • Pregnancy (Congenital Rubella Syndrome Risk)
  • Encephalitis
  • Thrombocytopenia
Overview

Rubella (German Measles)

1. Clinical Overview

Summary

Rubella is a mild viral illness caused by the Rubella virus (Togaviridae family). In children and adults, it typically presents with low-grade fever, maculopapular rash (Starts on face, spreads downwards), and characteristic posterior cervical and suboccipital lymphadenopathy. The illness is usually self-limiting and mild. However, the critical importance of rubella lies in its teratogenic potential – infection during early pregnancy (Especially first trimester) can cause Congenital Rubella Syndrome (CRS), which includes cataracts, congenital heart defects, sensorineural deafness, and developmental delay. Rubella is now rare in countries with high MMR vaccination coverage but remains a concern in unvaccinated populations and imported cases. Rubella is a notifiable disease in the UK. Prevention through MMR vaccination is the key public health strategy. [1,2,3]

Clinical Pearls

"Mild in Children, Catastrophic in Pregnancy": Postnatal rubella is trivial. Congenital rubella causes devastating multi-system defects.

"Posterior Cervical + Suboccipital Lymphadenopathy": Classic finding. Nodes behind the ears and at the base of the skull.

"First Trimester = Highest Risk": Rubella infection in first 12 weeks of pregnancy = 85-90% risk of CRS or fetal loss.

"MMR Vaccine = Elimination": Rubella is vaccine-preventable. Two doses of MMR provide lifelong immunity.


2. Epidemiology

Demographics

FactorNotes
AgeHistorically affects children 5-9 years. Now rare due to vaccination.
SexEqual.
Incidence (UK)Very rare. less than 50 cases/year (Thanks to MMR).
GlobalRemains endemic in some developing countries with low vaccine coverage.

Transmission

FactorNotes
RouteRespiratory droplets. Direct contact with nasopharyngeal secretions.
Incubation Period14-21 days (Average 16-18 days).
Infectious Period7 days before rash to 7 days after rash appears. Most infectious when rash erupts.

3. Virology

Rubella Virus

FeatureNotes
FamilyTogaviridae.
GenusRubivirus.
GenomeSingle-stranded positive-sense RNA.
SerotypesOne serotype (Infection or vaccination confers lifelong immunity).

4. Clinical Presentation

Postnatal Rubella (Children/Adults)

FeatureNotes
Prodrome1-5 days. Low-grade fever, Malaise, Headache, Mild conjunctivitis, Coryza. Often minimal or absent in children.
LymphadenopathyPosterior Cervical, Suboccipital, Post-auricular. Tender. Appears before rash. Persists for weeks.
RashMaculopapular (Pink-red spots). Starts on face → Spreads to trunk and limbs within 24 hours. Fades by Day 3 ("Three-Day Measles"). Non-confluent.
Arthralgia / ArthritisCommon in adolescent girls and adult women. Affects fingers, Wrists, Knees. Self-limiting.
Subclinical Infection~25-50% of rubella infections are asymptomatic.

Differentiating Features (Rash)

FeatureRubellaMeasles
ProdromeMild / AbsentSevere (Cough, Coryza, Conjunctivitis)
Koplik's SpotsAbsentPresent
Rash ConfluenceNon-confluentConfluent
Duration3 days5-6 days
DesquamationNoneYes
SeverityMildSignificant

5. Congenital Rubella Syndrome (CRS)

Risk by Gestational Age

Timing of Maternal InfectionRisk of CRS
less than 12 weeks (First Trimester)85-90% risk of defects or fetal loss.
13-16 weeks~35% risk. Usually deafness alone.
>16 weeksLow risk. Deafness possible.
>20 weeksMinimal risk.

Classic Triad of CRS

DefectNotes
CataractsMay be unilateral or bilateral. Present at birth.
Congenital Heart DefectsPDA (Most common), Pulmonary artery stenosis, VSD.
Sensorineural DeafnessMost common single defect. May be only manifestation if infection after 16 weeks.

Extended CRS Features

SystemManifestations
EyesCataracts, Microphthalmia, Glaucoma, Retinopathy ("Salt and pepper").
CardiacPDA, Pulmonary stenosis, VSD, ASD.
HearingSensorineural deafness.
CNSMicrocephaly, Intellectual disability, Behavioural disorders, Meningoencephalitis.
HaematologicalThrombocytopenic purpura ("Blueberry muffin" rash), Haemolytic anaemia.
OtherHepatosplenomegaly, Jaundice, Low birth weight, IUGR, Bone lesions.

Late Manifestations of CRS

ManifestationNotes
Diabetes MellitusIncreased risk in adulthood.
Thyroid DisordersAutoimmune thyroiditis.
Progressive Rubella PanencephalitisRare. Neurological deterioration in second decade.

6. Investigations

Diagnosis (Postnatal Rubella)

TestNotes
Serology (IgM)Rubella-specific IgM (Positive from rash onset to 6-8 weeks). Confirms recent infection.
Serology (IgG)IgG seroconversion (4-fold rise in paired sera) confirms acute infection. Single positive IgG indicates past infection or vaccination.
PCRRubella RNA from throat swab, Urine, Blood. Useful in early infection.

Diagnosis (CRS / In Pregnancy)

TestNotes
Maternal SerologyIgM positive or IgG seroconversion = Recent infection. If IgG positive only and high avidity = Past infection (Reassuring).
Fetal DiagnosisRubella PCR on amniotic fluid (Amniocentesis after 15 weeks). Fetal blood (Cordocentesis) for IgM.
Infant Diagnosis (CRS)Persistent rubella IgM in infant. Rubella PCR (Pharynx, Urine – Babies can shed virus for months). Clinical features.

7. Management

Management Algorithm

       SUSPECTED RUBELLA
       (Rash, Lymphadenopathy, Exposure history)
                     ↓
       CONFIRM DIAGNOSIS
       - Rubella IgM serology
       - OR Rubella PCR (Throat swab, Urine)
                     ↓
       NOTIFY PUBLIC HEALTH
       (Rubella is a NOTIFIABLE DISEASE)
                     ↓
       POSTNATAL RUBELLA (Non-Pregnant)
    ┌──────────────────────────────────────────────────────────┐
    │  SUPPORTIVE CARE                                         │
    │  - Rest                                                  │
    │  - Fluids                                                │
    │  - Paracetamol for fever/Arthralgia                      │
    │  - Self-limiting (3-5 days)                              │
    │                                                          │
    │  ISOLATION:                                              │
    │  - Avoid contact with pregnant women                     │
    │  - School exclusion for 5 days after rash onset          │
    └──────────────────────────────────────────────────────────┘
                     ↓
       RUBELLA IN PREGNANCY
    ┌──────────────────────────────────────────────────────────┐
    │  URGENT REFERRAL TO OBSTETRIC/FETAL MEDICINE             │
    │  - Confirm diagnosis (Serology, IgM, Avidity)            │
    │  - Counselling on CRS risk (Based on gestation)          │
    │  - Fetal assessment (USS, Amniocentesis)                 │
    │  - Discuss options (Including termination if less than 16 weeks)  │
    │  - Public Health notification                            │
    └──────────────────────────────────────────────────────────┘
                     ↓
       CONGENITAL RUBELLA SYNDROME (CRS)
       - Multidisciplinary team (Paediatrics, Cardiology, Ophthalmology,
         Audiology, Developmental)
       - Supportive/Corrective treatment (Cataract surgery, Cardiac surgery)
       - Hearing aids/Cochlear implants
       - Developmental support and early intervention
       - Infection control (Infants shed virus for months – Isolate from
         pregnant women)

Prevention (Key Strategy)

MeasureNotes
MMR VaccineLive attenuated. Dose 1: 12-13 months. Dose 2: 3 years 4 months. Two doses = 99% protection.
Pre-Pregnancy ScreeningCheck rubella IgG status. Vaccinate susceptible women BEFORE pregnancy. Avoid pregnancy for 1 month post-vaccination.
Postpartum VaccinationIf seronegative in pregnancy, Vaccinate immediately postpartum (Before discharge).
Contact TracingIdentify susceptible pregnant contacts. Serology. Immunoglobulin NOT effective for post-exposure prophylaxis.

8. Complications

Postnatal Rubella

ComplicationNotes
Arthralgia / ArthritisCommon in adolescent/Adult females. Transient.
ThrombocytopeniaRare. Self-limiting.
EncephalitisRare (~1 in 6000). Post-infectious. Recovery usually good.

Congenital Rubella Syndrome

ComplicationNotes
CRS FeaturesAs above (Cataracts, CHD, Deafness, etc.).
Late-Onset DiabetesIncreased risk.
Progressive PanencephalitisRare. Neurodegeneration in second decade.

9. Prognosis and Outcomes
FactorNotes
Postnatal RubellaExcellent. Self-limiting. Full recovery.
CRSDepends on severity. Significant long-term morbidity. Lifelong support often needed.

10. Evidence and Guidelines

Key Guidelines

GuidelineOrganisationKey Recommendations
Rubella in PregnancyPHE / UKHSAUrgent serology confirmation. Counselling. Fetal assessment. Notification.
MMR VaccinationJCVI / Green BookTwo doses. Universal immunisation. Pre-pregnancy screening.

11. Patient and Layperson Explanation

What is Rubella?

Rubella (German Measles) is a viral infection that causes a mild illness with a rash and swollen glands. In children, it is usually very mild and gets better on its own in a few days.

Why is it important?

The danger of rubella is if a pregnant woman catches it, especially in the first 3 months. The virus can seriously harm the developing baby, causing problems with the heart, eyes, hearing, and brain – called Congenital Rubella Syndrome.

What are the symptoms?

  • Low-grade fever.
  • Pink-red rash starting on the face and spreading down.
  • Swollen glands behind the ears and at the back of the neck.
  • Joint aches (Especially in women).

Many people have no symptoms at all.

How can it be prevented?

The MMR vaccine protects against Rubella. Two doses provide lifelong protection. It is important for:

  • All children (At 12-13 months and again at 3-4 years).
  • Women planning pregnancy who are not immune.

What if I'm pregnant and exposed to Rubella?

Contact your GP or midwife immediately. A blood test can check if you are immune. If you are not immune and have been exposed, you will be referred for specialist advice.


12. References

Primary Sources

  1. Public Health England. Rubella: the green book, chapter 28. 2013 (Updated 2019).
  2. Banatvala JE, et al. Rubella. Lancet. 2004;363(9415):1127-1137. PMID: 15064032.
  3. World Health Organization. Rubella vaccines: WHO position paper. Wkly Epidemiol Rec. 2020;95(27):306-324.

13. Examination Focus

Common Exam Questions

  1. Classic Lymphadenopathy: "Which lymph nodes are characteristically enlarged in Rubella?"
    • Answer: Posterior Cervical, Suboccipital, Post-auricular.
  2. CRS Triad: "What is the classic triad of Congenital Rubella Syndrome?"
    • Answer: Cataracts, Congenital Heart Defects (PDA), Sensorineural Deafness.
  3. Highest Risk Gestation: "At what stage of pregnancy is rubella infection most likely to cause CRS?"
    • Answer: First Trimester (less than 12 weeks) – 85-90% risk.
  4. Prevention: "How is Rubella prevented?"
    • Answer: MMR Vaccination (Two doses).

Viva Points

  • Three-Day Measles: Rubella rash lasts ~3 days (vs Measles ~5-6 days).
  • Notifiable Disease: Report to Public Health.
  • Vaccine Timing in Pregnancy: Do NOT vaccinate in pregnancy. Vaccinate postpartum if seronegative. Avoid pregnancy for 1 month post-vaccination.
  • Blueberry Muffin Baby: Thrombocytopenic purpura in CRS.

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.

Last updated: 2025-12-25

At a Glance

EvidenceHigh
Last Updated2025-12-25

Red Flags

  • Pregnancy (Congenital Rubella Syndrome Risk)
  • Encephalitis
  • Thrombocytopenia

Clinical Pearls

  • **"Mild in Children, Catastrophic in Pregnancy"**: Postnatal rubella is trivial. Congenital rubella causes devastating multi-system defects.
  • **"Posterior Cervical + Suboccipital Lymphadenopathy"**: Classic finding. Nodes behind the ears and at the base of the skull.
  • **"First Trimester = Highest Risk"**: Rubella infection in first 12 weeks of pregnancy = 85-90% risk of CRS or fetal loss.
  • **"MMR Vaccine = Elimination"**: Rubella is vaccine-preventable. Two doses of MMR provide lifelong immunity.

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines